<DOC>
	<DOCNO>NCT00767000</DOCNO>
	<brief_summary>The purpose study test effect MK-0941 add-on therapy participant take insulin type 2 diabetes mellitus . The primary hypothesis study treatment MK-0941 add insulin provide great reduction hemoglobin A1c ( HbA1c ) level placebo add insulin 14 week , MK-0941 well-tolerated 1 dos demonstrate efficacy .</brief_summary>
	<brief_title>Dose Range Finding Study MK-0941 Patients With Type 2 Diabetes Mellitus Insulin ( MK-0941-007 AM3 EXT1 AM1 ) ( TERMINATED )</brief_title>
	<detailed_description>This study 54-week randomize , double-blind base study optional 104-week extension study ( MK-0941-007-11 ) . Beginning Week 16 , participant randomize maximum dose MK-0941 could up-titrate MK-0941 40 mg three time daily . Participants complete 54-week base study eligible enter extension study remain treatment group assign base study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>type 2 diabetes mellitus body mass index &gt; 20 &lt; 43 kg/m^2 male , female unlikely conceive currently stable dose insulin without metformin Type 2 diabetes mellitus Extension Study complete base study either doubleblind study medication part posttreatment follow population ≥85 % compliance doubleblind openlabel medication base study doubleblind treatment period history Type 1 diabetes mellitus ketoacidosis receive 1 week thiazolidinedione ( pioglitazone rosiglitazone ) therapy injectable increatinbased therapy ( Byetta ) within prior 8 week ≥2 episode lifetime &gt; 1 episode within past year result hypoglycemic seizure , coma , unconsciousness weight loss program maintenance phase , patient take weight loss medication ( e.g. , orlistat , sibutramine , rimonabant ) within 8 week Visit 1 undergone surgery within 30 day prior Visit 1 plan major surgery</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>